Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...
About the author: John Crawford is the founder and managing director of Crawford Works, and an independent consultant with experience in digital health. Until 2018, he was the Healthcare Industry Leader for Europe at IBM, and, from 2016 to 2018, a director of the Global Board of HIMSS, owner of MobiHealthNews. He is now an advisory consultant for HIMSS in Europe. The opinions in this piece are...
This morning Medopad, an artificial intelligence-enabled patient data collection and analytics platform, landed $25 million in Series B funding. The last round was led by pharma giant Bayer’s venture capital branch Leaps by Bayer.
This new announcement brings the UK-based company’s total funding to $50 million, and comes roughly a year and a half after it closed its $28 million Series A round....
Pear Therapeutics has announced a new deal with Ironwood Pharmaceuticals that will explore the platform’s potential for patients with certain gastrointestinal (GI) conditions.
“We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of [prescription digital therapeutics] in treating GI diseases,” Dr. Corey McCann, president and...
The past few days have seen new pivotal trial announcements from two startups eyeing FDA submissions for their digital health offerings.
On Thursday Cognoa unveiled an investigation for its pediatric development monitoring and diagnostic tool. This will be a multi-site, prospective, blinded, active comparator study of the tool, which is intended to support primary care autism diagnoses among...
Editor's Note: This story has been updated with additional quotes from Pear Therapeutics.
The poster child of digital therapeutics-pharma collaborations is soon to be no more, as Novartis division Sandoz announced that it is handing sole responsibility for the commercialization of the reSET and reSET-O prescription digital therapeutics back to Pear Therapeutics.
“Pear and Sandoz previously signed...
Credit: Ieso Digital Health
The digital therapeutics field has attracted the interest of major players in the healthcare industry lately, from big pharma to the NHS. But there is debate among stakeholders around issues including reimbursement, regulation and business models that work.
The space, however, continues to grow, and Cambridge-headquartered Ieso Digital Health unveiled earlier this year plans to build an...
Photo credit: Rock Health
A decade ago digital health was a relatively new term, largely without name recognition. Today, the venture dollars tell a new story, with $8.1 billion poured into the space in 2018 alone, according to a Rock Health report. Still, most healthcare stakeholders agree digital health is still in its early days and is grappling with questions about its place in the health ecosystem.
Founded in 2010,...
Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California.
Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home...
ATENTIV, maker of a video game-based intervention for ADHD, has partnered with Children’s Specialized Hospital’s Center for Discovery, Innovation and Development (CDID) to explore a novel care model blending both behavioral and primary care.
Of particular note, ATENTIV and CDID, part of the RWJBarnabas Health system in New Jersey, will be investigating how to deploy the therapy, called...
